Werfen Life Divests to Focus on the Hemostasis Market

Some large and small healthcare players are shifting their portfolios to focus on the hemostasis analyzer market, which is expected to reach nearly $5 billion by 2021.

Radiopharmacies Now on Dealmakers’ Radar

You can’t get much more “specialty” in the specialty pharmacy business than to deal in radiopharmaceuticals. Two recent deals, announced in August, show this area is heating up. IBA Molecular, a global maker and distributor of radiopharmaceutical products, agreed to pay approximately $613 million for Mallinckrodt‘s (NYSE: MNK) nuclear imaging business, including a portfolio of […]

The Gores Group Exits with $1.325 Billion

Last week’s Biggest Deal was Mallinckrodt plc’s (NYSE: MNK) $1.325 billion acquisition of Therakos, Inc., an immunotherapy company, from The Gores Group. Gores acquired Therakos back in October 2012 for an undisclosed price from Ortho-Clinical Diagnostics. The transaction is expected to be accretive by no less than $0.10 per share to Mallinckrodt’s adjusted diluted fiscal […]

Busy Year for Billion-Dollar Health Care Deals

Last week we noted that April was a slow month for healthcare deals. Then we checked our database, DealSearchOnline.com, and discovered there have been 19 billion-dollar deal announcements already in 2015, through May 8th, with a combined total of $103.6 billion. The total for the entire year is about to top $120 billion, on 487 […]

March Healthcare M&A Madness

March isn’t quite over as we write this, and neither is the madness—which won’t stop us from posting the biggest deals of the month. As of Friday, March 27, $34.4 billion has been committed to finance about 105 transactions. Of course, $21 billion of that comes from the AbbVie (NYSE: ABBV) acquisition of Pharmacyclics (NASDAQ: […]

Year’s Biggest Billion-Dollar Deals Top $64 Billion

Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.